CLTR COULTER PHARMACEUTICAL Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (450)	12/9/1999 12:36:00 PM
From: tnsaf	Read Replies (1) of 666

<<We once concluded that NERX was using C2B8 for initial studies>> The table of clinical trials lists it as C2B8-SA,90Y-B. There is a reference listed as "Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma: preliminary results [abstract] J Nucl Med 1999, 40:19", but I can't find it listed on the Journal of Nuclear Medicine's web site for Jan - Nov. The page number indicates it should be in the January issue. Too bad they aren't listed on Saturday's Informed Investors in Seattle, or Mike could ask about it. Jason

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next